Lv35
230 积分 2025-07-17 加入
The cartography of KRAS inhibitor resistance in colorectal cancer
10天前
已完结
Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01
22天前
已关闭
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer
22天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
1个月前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
1个月前
已关闭
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
1个月前
已完结
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer
1个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
1个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
1个月前
已完结
皖公网安备34019202002308
